Sanofi Q3 well on track
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/9/2026
- Wall St rises as chip stocks' gains offset Middle East jitters
- Software stocks slide as Starbucks builds AI tools to replace vendor software
- Applied Materials surges as CEO signals multi-year chip boom
- Oil prices slide over 1% as US-Iran conflict clouds Hormuz reopening
- Meta falls as massive AI infrastructure spending plans overshadow chip progress
- Morgan Stanley Reiterates Overweight Rating on Rocket Lab USA (RKLB), Bull Case Raised to $293
- GameStop stockholders approve share count increase to 2.5 billion
- Crude Inventory Rose 3 Million Barrels Last Week - EIA
- AI bubble fears mount as Zuckerberg admits agent delays and Burry shorts sector
- S&P 500 ends down after Trump says Iran deal is 'over'
Sanofi (SNY) Reports Q3 EPS of EUR1.92
October 31, 2019 8:05 AM EDTSanofi (NASDAQ: SNY) reported Q3 EPS of EUR1.92. Revenue for the quarter came in at EUR9.5 billion versus the consensus estimate of EUR10.38 billion.
Third-quarter 2019 sales performance(3) led by Sanofi Genzyme and Emerging Markets
Net sales were 9,499 million, up 1.1% on a reported basis, down 1.1%(3) at CER and up 0.5% at CER/CS(4).Sanofi Genzyme sales increased 19.5% driven by continued strong uptake of Dupixent®.Vaccines sales decreased 9.8% reflecting anticipated weighting of U.S. flu vaccines supply towards fourth quarter.CHC sales up 0.4%, impacted by Zantac® voluntary... More